<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta charset="utf-8"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><meta name="description" content="(Deprecated, use dfTrials2Long and dfName2Value!)
The function uses a name (key) to extract an element
from a list in a data.frame such as obtained with
dbGetFieldsIntoDf. This helps to simplify
working with nested lists and with complex structures."><title>Extract named element(s) from list(s) into long-format
data frame — dfListExtractKey • ctrdata</title><script src="../deps/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><link href="../deps/bootstrap-5.1.3/bootstrap.min.css" rel="stylesheet"><script src="../deps/bootstrap-5.1.3/bootstrap.bundle.min.js"></script><!-- Font Awesome icons --><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/all.min.css" integrity="sha256-mmgLkCYLUQbXn0B1SRqzHar6dCnv9oZFPEC1g1cwlkk=" crossorigin="anonymous"><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/v4-shims.min.css" integrity="sha256-wZjR52fzng1pJHwx4aV2AO3yyTOXrcDW7jBpJtTwVxw=" crossorigin="anonymous"><!-- bootstrap-toc --><script src="https://cdn.rawgit.com/afeld/bootstrap-toc/v1.0.1/dist/bootstrap-toc.min.js"></script><!-- headroom.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/headroom.min.js" integrity="sha256-AsUX4SJE1+yuDu5+mAVzJbuYNPHj/WroHuZ8Ir/CkE0=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/jQuery.headroom.min.js" integrity="sha256-ZX/yNShbjqsohH1k95liqY9Gd8uOiE1S4vZc+9KQ1K4=" crossorigin="anonymous"></script><!-- clipboard.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><!-- search --><script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/6.4.6/fuse.js" integrity="sha512-zv6Ywkjyktsohkbp9bb45V6tEMoWhzFzXis+LrMehmJZZSys19Yxf1dopHx7WzIKxr5tK2dVcYmaCk2uqdjF4A==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/autocomplete.js/0.38.0/autocomplete.jquery.min.js" integrity="sha512-GU9ayf+66Xx2TmpxqJpliWbT5PiGYxpaG8rfnBEk1LL8l1KGkRShhngwdXK1UgqhAzWpZHSiYPc09/NwDQIGyg==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/mark.min.js" integrity="sha512-5CYOlHXGh6QpOFA/TeTylKLWfB3ftPsde7AnmhuitiTX4K5SqCLBeKro6sPS8ilsz1Q4NRx3v8Ko2IBiszzdww==" crossorigin="anonymous"></script><!-- pkgdown --><script src="../pkgdown.js"></script><meta property="og:title" content="Extract named element(s) from list(s) into long-format
data frame — dfListExtractKey"><meta property="og:description" content="(Deprecated, use dfTrials2Long and dfName2Value!)
The function uses a name (key) to extract an element
from a list in a data.frame such as obtained with
dbGetFieldsIntoDf. This helps to simplify
working with nested lists and with complex structures."><meta name="twitter:card" content="summary_large_image"><meta name="twitter:creator" content="@rfhb"><meta name="twitter:site" content="@rfhb"><!-- mathjax --><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js" integrity="sha256-nvJJv9wWKEm88qvoQl9ekL2J+k/RWIsaSScxxlsrv8k=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/config/TeX-AMS-MML_HTMLorMML.js" integrity="sha256-84DKXVJXs0/F8OTMzX4UR909+jtl4G7SPypPavF+GfA=" crossorigin="anonymous"></script><!--[if lt IE 9]>
<script src="https://oss.maxcdn.com/html5shiv/3.7.3/html5shiv.min.js"></script>
<script src="https://oss.maxcdn.com/respond/1.4.2/respond.min.js"></script>
<![endif]--></head><body>
    <a href="#main" class="visually-hidden-focusable">Skip to contents</a>
    

    <nav class="navbar fixed-top navbar-light navbar-expand-lg bg-light"><div class="container">
    
    <a class="navbar-brand me-2" href="../index.html">ctrdata</a>

    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="Released version">1.10.1.9006</small>

    
    <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
      <span class="navbar-toggler-icon"></span>
    </button>

    <div id="navbar" class="collapse navbar-collapse ms-3">
      <ul class="navbar-nav me-auto"><li class="active nav-item">
  <a class="nav-link" href="../reference/index.html">Reference</a>
</li>
<li class="nav-item dropdown">
  <a href="#" class="nav-link dropdown-toggle" data-bs-toggle="dropdown" role="button" aria-expanded="false" aria-haspopup="true" id="dropdown-articles">Articles</a>
  <div class="dropdown-menu" aria-labelledby="dropdown-articles">
    <a class="dropdown-item" href="../articles/ctrdata_install.html">Install R package ctrdata</a>
    <a class="dropdown-item" href="../articles/ctrdata_retrieve.html">Retrieve clinical trial information</a>
    <a class="dropdown-item" href="../articles/ctrdata_summarise.html">Summarise and analyse clinical trial information</a>
  </div>
</li>
<li class="nav-item">
  <a class="nav-link" href="../news/index.html">Changelog</a>
</li>
      </ul><form class="form-inline my-2 my-lg-0" role="search">
        <input type="search" class="form-control me-sm-2" aria-label="Toggle navigation" name="search-input" data-search-index="../search.json" id="search-input" placeholder="Search for" autocomplete="off"></form>

      <ul class="navbar-nav"><li class="nav-item">
  <a class="external-link nav-link" href="https://github.com/rfhb/ctrdata/" aria-label="github">
    <span class="fab fa fab fa-github fa-lg"></span>
     
  </a>
</li>
      </ul></div>

    
  </div>
</nav><div class="container template-reference-topic">
<div class="row">
  <main id="main" class="col-md-9"><div class="page-header">
      <img src="" class="logo" alt=""><h1>Extract named element(s) from list(s) into long-format
data frame</h1>
      <small class="dont-index">Source: <a href="https://github.com/rfhb/ctrdata/blob/HEAD/R/utils.R" class="external-link"><code>R/utils.R</code></a></small>
      <div class="d-none name"><code>dfListExtractKey.Rd</code></div>
    </div>

    <div class="ref-description section level2">
    <p>(Deprecated, use <a href="dfTrials2Long.html">dfTrials2Long</a> and <a href="dfName2Value.html">dfName2Value</a>!)
The function uses a name (key) to extract an element
from a list in a data.frame such as obtained with
<a href="dbGetFieldsIntoDf.html">dbGetFieldsIntoDf</a>. This helps to simplify
working with nested lists and with complex structures.</p>
    </div>

    <div class="section level2">
    <h2 id="ref-usage">Usage<a class="anchor" aria-label="anchor" href="#ref-usage"></a></h2>
    <div class="sourceCode"><pre class="sourceCode r"><code><span><span class="fu">dfListExtractKey</span><span class="op">(</span><span class="va">df</span>, list.key <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/list.html" class="external-link">list</a></span><span class="op">(</span><span class="fu"><a href="https://rdrr.io/r/base/c.html" class="external-link">c</a></span><span class="op">(</span><span class="st">"endPoints.endPoint"</span>, <span class="st">"^title"</span><span class="op">)</span><span class="op">)</span><span class="op">)</span></span></code></pre></div>
    </div>

    <div class="section level2">
    <h2 id="arguments">Arguments<a class="anchor" aria-label="anchor" href="#arguments"></a></h2>
    <dl><dt>df</dt>
<dd><p>A data frame (or tibble)</p></dd>


<dt>list.key</dt>
<dd><p>A list of pairs of list names and
key names, where the list name corresponds to the
name of a column in <code>df</code> that holds a list and
the name of the key identifies the element to be
extracted. See example.</p></dd>

</dl></div>
    <div class="section level2">
    <h2 id="value">Value<a class="anchor" aria-label="anchor" href="#value"></a></h2>
    

<p>A data frame (or tibble, if <code>dplyr</code> is loaded)
 in long format with columns
 name (identifying the full path in the data frame,
 "&lt;list&gt;.&lt;key&gt;"), _id (of the trial record), value
 (of name per _id), item (number of value of name
 per _id).</p>
    </div>

    <div class="section level2">
    <h2 id="ref-examples">Examples<a class="anchor" aria-label="anchor" href="#ref-examples"></a></h2>
    <div class="sourceCode"><pre class="sourceCode r"><code><span class="r-in"><span></span></span>
<span class="r-in"><span><span class="va">dbc</span> <span class="op">&lt;-</span> <span class="fu">nodbi</span><span class="fu">::</span><span class="fu"><a href="https://docs.ropensci.org/nodbi/reference/src_sqlite.html" class="external-link">src_sqlite</a></span><span class="op">(</span></span></span>
<span class="r-in"><span>   dbname <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/system.file.html" class="external-link">system.file</a></span><span class="op">(</span><span class="st">"extdata"</span>, <span class="st">"demo.sqlite"</span>, package <span class="op">=</span> <span class="st">"ctrdata"</span><span class="op">)</span>,</span></span>
<span class="r-in"><span>   collection <span class="op">=</span> <span class="st">"my_trials"</span><span class="op">)</span></span></span>
<span class="r-in"><span></span></span>
<span class="r-in"><span><span class="va">df</span> <span class="op">&lt;-</span> <span class="fu"><a href="dbGetFieldsIntoDf.html">dbGetFieldsIntoDf</a></span><span class="op">(</span></span></span>
<span class="r-in"><span>  fields <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/c.html" class="external-link">c</a></span><span class="op">(</span></span></span>
<span class="r-in"><span>    <span class="st">"endPoints.endPoint"</span>,</span></span>
<span class="r-in"><span>    <span class="st">"subjectDisposition.postAssignmentPeriods"</span><span class="op">)</span>,</span></span>
<span class="r-in"><span>  con <span class="op">=</span> <span class="va">dbc</span><span class="op">)</span></span></span>
<span class="r-msg co"><span class="r-pr">#&gt;</span> endPoints.endPoint... </span>
<span class="r-msg co"><span class="r-pr">#&gt;</span>     </span>
<span class="r-msg co"><span class="r-pr">#&gt;</span> . </span>
<span class="r-msg co"><span class="r-pr">#&gt;</span> </span>
<span class="r-msg co"><span class="r-pr">#&gt;</span> subjectDisposition.postAssignmentPeriods... </span>
<span class="r-msg co"><span class="r-pr">#&gt;</span>     </span>
<span class="r-msg co"><span class="r-pr">#&gt;</span> . </span>
<span class="r-in"><span></span></span>
<span class="r-in"><span><span class="fu"><a href="https://rdrr.io/r/base/warning.html" class="external-link">suppressWarnings</a></span><span class="op">(</span></span></span>
<span class="r-in"><span>  <span class="fu">dfListExtractKey</span><span class="op">(</span></span></span>
<span class="r-in"><span>    df <span class="op">=</span> <span class="va">df</span>,</span></span>
<span class="r-in"><span>    list.key <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/list.html" class="external-link">list</a></span><span class="op">(</span></span></span>
<span class="r-in"><span>        <span class="fu"><a href="https://rdrr.io/r/base/c.html" class="external-link">c</a></span><span class="op">(</span><span class="st">"endPoints.endPoint"</span>,</span></span>
<span class="r-in"><span>          <span class="st">"^title"</span><span class="op">)</span>,</span></span>
<span class="r-in"><span>        <span class="fu"><a href="https://rdrr.io/r/base/c.html" class="external-link">c</a></span><span class="op">(</span><span class="st">"subjectDisposition.postAssignmentPeriods"</span>,</span></span>
<span class="r-in"><span>          <span class="st">"arms.arm.type.value"</span><span class="op">)</span><span class="op">)</span></span></span>
<span class="r-in"><span><span class="op">)</span><span class="op">)</span></span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span>                         name                _id</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 1   endPoints.endPoint.title 2007-004277-26-3RD</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 2   endPoints.endPoint.title 2007-004277-26-3RD</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 3   endPoints.endPoint.title 2007-004277-26-3RD</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 4   endPoints.endPoint.title 2007-004277-26-3RD</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 5   endPoints.endPoint.title 2007-004277-26-3RD</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 6   endPoints.endPoint.title 2007-004277-26-3RD</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 7   endPoints.endPoint.title  2007-004277-26-AT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 8   endPoints.endPoint.title  2007-004277-26-AT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 9   endPoints.endPoint.title  2007-004277-26-AT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 10  endPoints.endPoint.title  2007-004277-26-AT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 11  endPoints.endPoint.title  2007-004277-26-AT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 12  endPoints.endPoint.title  2007-004277-26-AT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 13  endPoints.endPoint.title  2007-004277-26-BE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 14  endPoints.endPoint.title  2007-004277-26-BE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 15  endPoints.endPoint.title  2007-004277-26-BE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 16  endPoints.endPoint.title  2007-004277-26-BE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 17  endPoints.endPoint.title  2007-004277-26-BE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 18  endPoints.endPoint.title  2007-004277-26-BE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 19  endPoints.endPoint.title  2007-004277-26-DE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 20  endPoints.endPoint.title  2007-004277-26-DE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 21  endPoints.endPoint.title  2007-004277-26-DE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 22  endPoints.endPoint.title  2007-004277-26-DE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 23  endPoints.endPoint.title  2007-004277-26-DE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 24  endPoints.endPoint.title  2007-004277-26-DE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 25  endPoints.endPoint.title  2007-004277-26-DK</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 26  endPoints.endPoint.title  2007-004277-26-DK</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 27  endPoints.endPoint.title  2007-004277-26-DK</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 28  endPoints.endPoint.title  2007-004277-26-DK</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 29  endPoints.endPoint.title  2007-004277-26-DK</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 30  endPoints.endPoint.title  2007-004277-26-DK</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 31  endPoints.endPoint.title  2007-004277-26-ES</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 32  endPoints.endPoint.title  2007-004277-26-ES</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 33  endPoints.endPoint.title  2007-004277-26-ES</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 34  endPoints.endPoint.title  2007-004277-26-ES</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 35  endPoints.endPoint.title  2007-004277-26-ES</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 36  endPoints.endPoint.title  2007-004277-26-ES</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 37  endPoints.endPoint.title  2007-004277-26-FR</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 38  endPoints.endPoint.title  2007-004277-26-FR</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 39  endPoints.endPoint.title  2007-004277-26-FR</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 40  endPoints.endPoint.title  2007-004277-26-FR</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 41  endPoints.endPoint.title  2007-004277-26-FR</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 42  endPoints.endPoint.title  2007-004277-26-FR</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 43  endPoints.endPoint.title  2007-004277-26-GB</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 44  endPoints.endPoint.title  2007-004277-26-GB</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 45  endPoints.endPoint.title  2007-004277-26-GB</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 46  endPoints.endPoint.title  2007-004277-26-GB</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 47  endPoints.endPoint.title  2007-004277-26-GB</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 48  endPoints.endPoint.title  2007-004277-26-GB</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 49  endPoints.endPoint.title  2007-004277-26-IE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 50  endPoints.endPoint.title  2007-004277-26-IE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 51  endPoints.endPoint.title  2007-004277-26-IE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 52  endPoints.endPoint.title  2007-004277-26-IE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 53  endPoints.endPoint.title  2007-004277-26-IE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 54  endPoints.endPoint.title  2007-004277-26-IE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 55  endPoints.endPoint.title  2007-004277-26-IT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 56  endPoints.endPoint.title  2007-004277-26-IT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 57  endPoints.endPoint.title  2007-004277-26-IT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 58  endPoints.endPoint.title  2007-004277-26-IT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 59  endPoints.endPoint.title  2007-004277-26-IT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 60  endPoints.endPoint.title  2007-004277-26-IT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 61  endPoints.endPoint.title  2007-004277-26-NL</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 62  endPoints.endPoint.title  2007-004277-26-NL</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 63  endPoints.endPoint.title  2007-004277-26-NL</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 64  endPoints.endPoint.title  2007-004277-26-NL</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 65  endPoints.endPoint.title  2007-004277-26-NL</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 66  endPoints.endPoint.title  2007-004277-26-NL</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 67  endPoints.endPoint.title  2007-004277-26-PT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 68  endPoints.endPoint.title  2007-004277-26-PT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 69  endPoints.endPoint.title  2007-004277-26-PT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 70  endPoints.endPoint.title  2007-004277-26-PT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 71  endPoints.endPoint.title  2007-004277-26-PT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 72  endPoints.endPoint.title  2007-004277-26-PT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 73  endPoints.endPoint.title  2011-001033-16-AT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 74  endPoints.endPoint.title  2011-001033-16-AT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 75  endPoints.endPoint.title  2011-001033-16-AT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 76  endPoints.endPoint.title  2011-001033-16-AT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 77  endPoints.endPoint.title  2011-001033-16-AT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 78  endPoints.endPoint.title  2011-001033-16-AT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 79  endPoints.endPoint.title  2011-001033-16-AT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 80  endPoints.endPoint.title  2011-001033-16-AT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 81  endPoints.endPoint.title  2011-001033-16-AT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 82  endPoints.endPoint.title  2011-001033-16-DK</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 83  endPoints.endPoint.title  2011-001033-16-DK</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 84  endPoints.endPoint.title  2011-001033-16-DK</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 85  endPoints.endPoint.title  2011-001033-16-DK</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 86  endPoints.endPoint.title  2011-001033-16-DK</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 87  endPoints.endPoint.title  2011-001033-16-DK</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 88  endPoints.endPoint.title  2011-001033-16-DK</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 89  endPoints.endPoint.title  2011-001033-16-DK</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 90  endPoints.endPoint.title  2011-001033-16-DK</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 91  endPoints.endPoint.title  2011-001033-16-ES</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 92  endPoints.endPoint.title  2011-001033-16-ES</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 93  endPoints.endPoint.title  2011-001033-16-ES</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 94  endPoints.endPoint.title  2011-001033-16-ES</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 95  endPoints.endPoint.title  2011-001033-16-ES</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 96  endPoints.endPoint.title  2011-001033-16-ES</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 97  endPoints.endPoint.title  2011-001033-16-ES</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 98  endPoints.endPoint.title  2011-001033-16-ES</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 99  endPoints.endPoint.title  2011-001033-16-ES</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 100 endPoints.endPoint.title  2011-001033-16-GB</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 101 endPoints.endPoint.title  2011-001033-16-GB</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 102 endPoints.endPoint.title  2011-001033-16-GB</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 103 endPoints.endPoint.title  2011-001033-16-GB</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 104 endPoints.endPoint.title  2011-001033-16-GB</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 105 endPoints.endPoint.title  2011-001033-16-GB</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 106 endPoints.endPoint.title  2011-001033-16-GB</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 107 endPoints.endPoint.title  2011-001033-16-GB</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 108 endPoints.endPoint.title  2011-001033-16-GB</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 109 endPoints.endPoint.title  2011-001033-16-GR</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 110 endPoints.endPoint.title  2011-001033-16-GR</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 111 endPoints.endPoint.title  2011-001033-16-GR</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 112 endPoints.endPoint.title  2011-001033-16-GR</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 113 endPoints.endPoint.title  2011-001033-16-GR</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 114 endPoints.endPoint.title  2011-001033-16-GR</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 115 endPoints.endPoint.title  2011-001033-16-GR</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 116 endPoints.endPoint.title  2011-001033-16-GR</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 117 endPoints.endPoint.title  2011-001033-16-GR</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 118 endPoints.endPoint.title  2011-001033-16-HU</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 119 endPoints.endPoint.title  2011-001033-16-HU</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 120 endPoints.endPoint.title  2011-001033-16-HU</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 121 endPoints.endPoint.title  2011-001033-16-HU</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 122 endPoints.endPoint.title  2011-001033-16-HU</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 123 endPoints.endPoint.title  2011-001033-16-HU</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 124 endPoints.endPoint.title  2011-001033-16-HU</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 125 endPoints.endPoint.title  2011-001033-16-HU</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 126 endPoints.endPoint.title  2011-001033-16-HU</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 127 endPoints.endPoint.title  2011-001033-16-LT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 128 endPoints.endPoint.title  2011-001033-16-LT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 129 endPoints.endPoint.title  2011-001033-16-LT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 130 endPoints.endPoint.title  2011-001033-16-LT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 131 endPoints.endPoint.title  2011-001033-16-LT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 132 endPoints.endPoint.title  2011-001033-16-LT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 133 endPoints.endPoint.title  2011-001033-16-LT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 134 endPoints.endPoint.title  2011-001033-16-LT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 135 endPoints.endPoint.title  2011-001033-16-LT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 136 endPoints.endPoint.title  2011-001033-16-PL</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 137 endPoints.endPoint.title  2011-001033-16-PL</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 138 endPoints.endPoint.title  2011-001033-16-PL</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 139 endPoints.endPoint.title  2011-001033-16-PL</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 140 endPoints.endPoint.title  2011-001033-16-PL</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 141 endPoints.endPoint.title  2011-001033-16-PL</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 142 endPoints.endPoint.title  2011-001033-16-PL</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 143 endPoints.endPoint.title  2011-001033-16-PL</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 144 endPoints.endPoint.title  2011-001033-16-PL</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 145 endPoints.endPoint.title  2011-001033-16-PT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 146 endPoints.endPoint.title  2011-001033-16-PT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 147 endPoints.endPoint.title  2011-001033-16-PT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 148 endPoints.endPoint.title  2011-001033-16-PT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 149 endPoints.endPoint.title  2011-001033-16-PT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 150 endPoints.endPoint.title  2011-001033-16-PT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 151 endPoints.endPoint.title  2011-001033-16-PT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 152 endPoints.endPoint.title  2011-001033-16-PT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 153 endPoints.endPoint.title  2011-001033-16-PT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 154 endPoints.endPoint.title  2012-003632-23-AT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 155 endPoints.endPoint.title  2012-003632-23-AT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 156 endPoints.endPoint.title  2012-003632-23-AT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 157 endPoints.endPoint.title  2012-003632-23-AT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 158 endPoints.endPoint.title  2012-003632-23-AT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 159 endPoints.endPoint.title  2012-003632-23-AT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 160 endPoints.endPoint.title  2012-003632-23-AT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 161 endPoints.endPoint.title  2012-003632-23-AT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 162 endPoints.endPoint.title  2012-003632-23-CZ</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 163 endPoints.endPoint.title  2012-003632-23-CZ</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 164 endPoints.endPoint.title  2012-003632-23-CZ</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 165 endPoints.endPoint.title  2012-003632-23-CZ</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 166 endPoints.endPoint.title  2012-003632-23-CZ</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 167 endPoints.endPoint.title  2012-003632-23-CZ</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 168 endPoints.endPoint.title  2012-003632-23-CZ</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 169 endPoints.endPoint.title  2012-003632-23-CZ</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 170 endPoints.endPoint.title  2012-003632-23-DE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 171 endPoints.endPoint.title  2012-003632-23-DE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 172 endPoints.endPoint.title  2012-003632-23-DE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 173 endPoints.endPoint.title  2012-003632-23-DE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 174 endPoints.endPoint.title  2012-003632-23-DE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 175 endPoints.endPoint.title  2012-003632-23-DE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 176 endPoints.endPoint.title  2012-003632-23-DE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 177 endPoints.endPoint.title  2012-003632-23-DE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 178 endPoints.endPoint.title  2012-003632-23-ES</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 179 endPoints.endPoint.title  2012-003632-23-ES</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 180 endPoints.endPoint.title  2012-003632-23-ES</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 181 endPoints.endPoint.title  2012-003632-23-ES</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 182 endPoints.endPoint.title  2012-003632-23-ES</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 183 endPoints.endPoint.title  2012-003632-23-ES</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 184 endPoints.endPoint.title  2012-003632-23-ES</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 185 endPoints.endPoint.title  2012-003632-23-ES</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 186 endPoints.endPoint.title  2012-003632-23-GB</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 187 endPoints.endPoint.title  2012-003632-23-GB</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 188 endPoints.endPoint.title  2012-003632-23-GB</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 189 endPoints.endPoint.title  2012-003632-23-GB</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 190 endPoints.endPoint.title  2012-003632-23-GB</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 191 endPoints.endPoint.title  2012-003632-23-GB</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 192 endPoints.endPoint.title  2012-003632-23-GB</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 193 endPoints.endPoint.title  2012-003632-23-GB</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 194 endPoints.endPoint.title  2012-003632-23-IT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 195 endPoints.endPoint.title  2012-003632-23-IT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 196 endPoints.endPoint.title  2012-003632-23-IT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 197 endPoints.endPoint.title  2012-003632-23-IT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 198 endPoints.endPoint.title  2012-003632-23-IT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 199 endPoints.endPoint.title  2012-003632-23-IT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 200 endPoints.endPoint.title  2012-003632-23-IT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 201 endPoints.endPoint.title  2012-003632-23-IT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 202 endPoints.endPoint.title  2012-003632-23-SE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 203 endPoints.endPoint.title  2012-003632-23-SE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 204 endPoints.endPoint.title  2012-003632-23-SE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 205 endPoints.endPoint.title  2012-003632-23-SE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 206 endPoints.endPoint.title  2012-003632-23-SE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 207 endPoints.endPoint.title  2012-003632-23-SE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 208 endPoints.endPoint.title  2012-003632-23-SE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 209 endPoints.endPoint.title  2012-003632-23-SE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 210 endPoints.endPoint.title  2013-003629-27-BE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 211 endPoints.endPoint.title  2013-003629-27-BE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 212 endPoints.endPoint.title  2013-003629-27-BE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 213 endPoints.endPoint.title  2013-003629-27-BE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 214 endPoints.endPoint.title  2013-003629-27-BE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 215 endPoints.endPoint.title  2013-003629-27-BE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 216 endPoints.endPoint.title  2013-003629-27-BE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 217 endPoints.endPoint.title  2013-003629-27-BE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 218 endPoints.endPoint.title  2013-003629-27-BE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 219 endPoints.endPoint.title  2013-003629-27-DE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 220 endPoints.endPoint.title  2013-003629-27-DE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 221 endPoints.endPoint.title  2013-003629-27-DE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 222 endPoints.endPoint.title  2013-003629-27-DE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 223 endPoints.endPoint.title  2013-003629-27-DE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 224 endPoints.endPoint.title  2013-003629-27-DE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 225 endPoints.endPoint.title  2013-003629-27-DE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 226 endPoints.endPoint.title  2013-003629-27-DE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 227 endPoints.endPoint.title  2013-003629-27-DE</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 228 endPoints.endPoint.title  2013-003629-27-DK</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 229 endPoints.endPoint.title  2013-003629-27-DK</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 230 endPoints.endPoint.title  2013-003629-27-DK</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 231 endPoints.endPoint.title  2013-003629-27-DK</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 232 endPoints.endPoint.title  2013-003629-27-DK</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 233 endPoints.endPoint.title  2013-003629-27-DK</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 234 endPoints.endPoint.title  2013-003629-27-DK</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 235 endPoints.endPoint.title  2013-003629-27-DK</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 236 endPoints.endPoint.title  2013-003629-27-DK</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 237 endPoints.endPoint.title  2013-003629-27-ES</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 238 endPoints.endPoint.title  2013-003629-27-ES</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 239 endPoints.endPoint.title  2013-003629-27-ES</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 240 endPoints.endPoint.title  2013-003629-27-ES</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 241 endPoints.endPoint.title  2013-003629-27-ES</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 242 endPoints.endPoint.title  2013-003629-27-ES</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 243 endPoints.endPoint.title  2013-003629-27-ES</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 244 endPoints.endPoint.title  2013-003629-27-ES</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 245 endPoints.endPoint.title  2013-003629-27-ES</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 246 endPoints.endPoint.title  2013-003629-27-FR</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 247 endPoints.endPoint.title  2013-003629-27-FR</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 248 endPoints.endPoint.title  2013-003629-27-FR</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 249 endPoints.endPoint.title  2013-003629-27-FR</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 250 endPoints.endPoint.title  2013-003629-27-FR</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>                                                                                                                                                                                       value</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 1                                                                                  Relative Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted at Day 28</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 2                                                                                                     Mean Actual change from baseline in FEV1 percent predicted across 3 treatment courses</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 3                       Relative change from baseline in FEV1 percent predicted at Day 28 in subjects who received inhaled tobramycin for ≥ 84 days in the 12 months prior to randomization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 4   Mean Actual change from baseline in FEV1 percent predicted across 3 treatment courses in subjects who received inhaled tobramycin for ≥ 84 days in the 12 months prior to randomization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 5                                                                                                      Time to need for intravenous (IV) antipseudomonal antibiotics for respiratory events</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 6                                                                                                                                                 Time to first respiratory hospitalization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 7                                                                                  Relative Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted at Day 28</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 8                                                                                                     Mean Actual change from baseline in FEV1 percent predicted across 3 treatment courses</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 9                       Relative change from baseline in FEV1 percent predicted at Day 28 in subjects who received inhaled tobramycin for ≥ 84 days in the 12 months prior to randomization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 10  Mean Actual change from baseline in FEV1 percent predicted across 3 treatment courses in subjects who received inhaled tobramycin for ≥ 84 days in the 12 months prior to randomization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 11                                                                                                     Time to need for intravenous (IV) antipseudomonal antibiotics for respiratory events</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 12                                                                                                                                                Time to first respiratory hospitalization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 13                                                                                 Relative Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted at Day 28</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 14                                                                                                    Mean Actual change from baseline in FEV1 percent predicted across 3 treatment courses</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 15                      Relative change from baseline in FEV1 percent predicted at Day 28 in subjects who received inhaled tobramycin for ≥ 84 days in the 12 months prior to randomization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 16  Mean Actual change from baseline in FEV1 percent predicted across 3 treatment courses in subjects who received inhaled tobramycin for ≥ 84 days in the 12 months prior to randomization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 17                                                                                                     Time to need for intravenous (IV) antipseudomonal antibiotics for respiratory events</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 18                                                                                                                                                Time to first respiratory hospitalization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 19                                                                                 Relative Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted at Day 28</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 20                                                                                                    Mean Actual change from baseline in FEV1 percent predicted across 3 treatment courses</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 21                      Relative change from baseline in FEV1 percent predicted at Day 28 in subjects who received inhaled tobramycin for ≥ 84 days in the 12 months prior to randomization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 22  Mean Actual change from baseline in FEV1 percent predicted across 3 treatment courses in subjects who received inhaled tobramycin for ≥ 84 days in the 12 months prior to randomization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 23                                                                                                     Time to need for intravenous (IV) antipseudomonal antibiotics for respiratory events</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 24                                                                                                                                                Time to first respiratory hospitalization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 25                                                                                 Relative Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted at Day 28</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 26                                                                                                    Mean Actual change from baseline in FEV1 percent predicted across 3 treatment courses</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 27                      Relative change from baseline in FEV1 percent predicted at Day 28 in subjects who received inhaled tobramycin for ≥ 84 days in the 12 months prior to randomization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 28  Mean Actual change from baseline in FEV1 percent predicted across 3 treatment courses in subjects who received inhaled tobramycin for ≥ 84 days in the 12 months prior to randomization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 29                                                                                                     Time to need for intravenous (IV) antipseudomonal antibiotics for respiratory events</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 30                                                                                                                                                Time to first respiratory hospitalization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 31                                                                                 Relative Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted at Day 28</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 32                                                                                                    Mean Actual change from baseline in FEV1 percent predicted across 3 treatment courses</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 33                      Relative change from baseline in FEV1 percent predicted at Day 28 in subjects who received inhaled tobramycin for ≥ 84 days in the 12 months prior to randomization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 34  Mean Actual change from baseline in FEV1 percent predicted across 3 treatment courses in subjects who received inhaled tobramycin for ≥ 84 days in the 12 months prior to randomization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 35                                                                                                     Time to need for intravenous (IV) antipseudomonal antibiotics for respiratory events</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 36                                                                                                                                                Time to first respiratory hospitalization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 37                                                                                 Relative Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted at Day 28</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 38                                                                                                    Mean Actual change from baseline in FEV1 percent predicted across 3 treatment courses</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 39                      Relative change from baseline in FEV1 percent predicted at Day 28 in subjects who received inhaled tobramycin for ≥ 84 days in the 12 months prior to randomization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 40  Mean Actual change from baseline in FEV1 percent predicted across 3 treatment courses in subjects who received inhaled tobramycin for ≥ 84 days in the 12 months prior to randomization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 41                                                                                                     Time to need for intravenous (IV) antipseudomonal antibiotics for respiratory events</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 42                                                                                                                                                Time to first respiratory hospitalization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 43                                                                                 Relative Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted at Day 28</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 44                                                                                                    Mean Actual change from baseline in FEV1 percent predicted across 3 treatment courses</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 45                      Relative change from baseline in FEV1 percent predicted at Day 28 in subjects who received inhaled tobramycin for ≥ 84 days in the 12 months prior to randomization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 46  Mean Actual change from baseline in FEV1 percent predicted across 3 treatment courses in subjects who received inhaled tobramycin for ≥ 84 days in the 12 months prior to randomization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 47                                                                                                     Time to need for intravenous (IV) antipseudomonal antibiotics for respiratory events</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 48                                                                                                                                                Time to first respiratory hospitalization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 49                                                                                 Relative Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted at Day 28</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 50                                                                                                    Mean Actual change from baseline in FEV1 percent predicted across 3 treatment courses</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 51                      Relative change from baseline in FEV1 percent predicted at Day 28 in subjects who received inhaled tobramycin for ≥ 84 days in the 12 months prior to randomization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 52  Mean Actual change from baseline in FEV1 percent predicted across 3 treatment courses in subjects who received inhaled tobramycin for ≥ 84 days in the 12 months prior to randomization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 53                                                                                                     Time to need for intravenous (IV) antipseudomonal antibiotics for respiratory events</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 54                                                                                                                                                Time to first respiratory hospitalization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 55                                                                                 Relative Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted at Day 28</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 56                                                                                                    Mean Actual change from baseline in FEV1 percent predicted across 3 treatment courses</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 57                      Relative change from baseline in FEV1 percent predicted at Day 28 in subjects who received inhaled tobramycin for ≥ 84 days in the 12 months prior to randomization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 58  Mean Actual change from baseline in FEV1 percent predicted across 3 treatment courses in subjects who received inhaled tobramycin for ≥ 84 days in the 12 months prior to randomization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 59                                                                                                     Time to need for intravenous (IV) antipseudomonal antibiotics for respiratory events</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 60                                                                                                                                                Time to first respiratory hospitalization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 61                                                                                 Relative Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted at Day 28</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 62                                                                                                    Mean Actual change from baseline in FEV1 percent predicted across 3 treatment courses</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 63                      Relative change from baseline in FEV1 percent predicted at Day 28 in subjects who received inhaled tobramycin for ≥ 84 days in the 12 months prior to randomization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 64  Mean Actual change from baseline in FEV1 percent predicted across 3 treatment courses in subjects who received inhaled tobramycin for ≥ 84 days in the 12 months prior to randomization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 65                                                                                                     Time to need for intravenous (IV) antipseudomonal antibiotics for respiratory events</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 66                                                                                                                                                Time to first respiratory hospitalization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 67                                                                                 Relative Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted at Day 28</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 68                                                                                                    Mean Actual change from baseline in FEV1 percent predicted across 3 treatment courses</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 69                      Relative change from baseline in FEV1 percent predicted at Day 28 in subjects who received inhaled tobramycin for ≥ 84 days in the 12 months prior to randomization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 70  Mean Actual change from baseline in FEV1 percent predicted across 3 treatment courses in subjects who received inhaled tobramycin for ≥ 84 days in the 12 months prior to randomization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 71                                                                                                     Time to need for intravenous (IV) antipseudomonal antibiotics for respiratory events</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 72                                                                                                                                                Time to first respiratory hospitalization</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 73                                                                                                                                             Incidence rate of FVIII inhibitors (≥0.6 BU)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 74                                   Haemostatic effect of turoctocog alfa on treatment of bleeds assessed on a predefined four point scale: Excellent, Good, Moderate and None: Main phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 75                              Haemostatic effect of turoctocog alfa on treatment of bleeds assessed on a predefined four point scale: Excellent, Good, Moderate and None: Extension phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 76           Haemostatic effect of turoctocog alfa on treatment of bleeds assessed on a predefined four point scale: excellent, good, moderate and none: Combined main and extension phases</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 77                                                                                                                                                     Annualised bleeding rate: Main phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 78                                                                                                                                                Annualised bleeding rate: Extension phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 79                                                                                                                             Annualised bleeding rate: Combined main and extension phases</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 80                                                                                                                            Incidence rate of FVIII inhibitors (≥0.6 BU): Extension phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 81                                                                                                         Incidence rate of FVIII inhibitors (≥0.6 BU): Combined main and extension phases</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 82                                                                                                                                             Incidence rate of FVIII inhibitors (≥0.6 BU)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 83                                   Haemostatic effect of turoctocog alfa on treatment of bleeds assessed on a predefined four point scale: Excellent, Good, Moderate and None: Main phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 84                              Haemostatic effect of turoctocog alfa on treatment of bleeds assessed on a predefined four point scale: Excellent, Good, Moderate and None: Extension phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 85           Haemostatic effect of turoctocog alfa on treatment of bleeds assessed on a predefined four point scale: excellent, good, moderate and none: Combined main and extension phases</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 86                                                                                                                                                     Annualised bleeding rate: Main phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 87                                                                                                                                                Annualised bleeding rate: Extension phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 88                                                                                                                             Annualised bleeding rate: Combined main and extension phases</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 89                                                                                                                            Incidence rate of FVIII inhibitors (≥0.6 BU): Extension phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 90                                                                                                         Incidence rate of FVIII inhibitors (≥0.6 BU): Combined main and extension phases</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 91                                                                                                                                             Incidence rate of FVIII inhibitors (≥0.6 BU)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 92                                   Haemostatic effect of turoctocog alfa on treatment of bleeds assessed on a predefined four point scale: Excellent, Good, Moderate and None: Main phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 93                              Haemostatic effect of turoctocog alfa on treatment of bleeds assessed on a predefined four point scale: Excellent, Good, Moderate and None: Extension phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 94           Haemostatic effect of turoctocog alfa on treatment of bleeds assessed on a predefined four point scale: excellent, good, moderate and none: Combined main and extension phases</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 95                                                                                                                                                     Annualised bleeding rate: Main phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 96                                                                                                                                                Annualised bleeding rate: Extension phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 97                                                                                                                             Annualised bleeding rate: Combined main and extension phases</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 98                                                                                                                            Incidence rate of FVIII inhibitors (≥0.6 BU): Extension phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 99                                                                                                         Incidence rate of FVIII inhibitors (≥0.6 BU): Combined main and extension phases</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 100                                                                                                                                            Incidence rate of FVIII inhibitors (≥0.6 BU)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 101                                  Haemostatic effect of turoctocog alfa on treatment of bleeds assessed on a predefined four point scale: Excellent, Good, Moderate and None: Main phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 102                             Haemostatic effect of turoctocog alfa on treatment of bleeds assessed on a predefined four point scale: Excellent, Good, Moderate and None: Extension phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 103          Haemostatic effect of turoctocog alfa on treatment of bleeds assessed on a predefined four point scale: excellent, good, moderate and none: Combined main and extension phases</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 104                                                                                                                                                    Annualised bleeding rate: Main phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 105                                                                                                                                               Annualised bleeding rate: Extension phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 106                                                                                                                            Annualised bleeding rate: Combined main and extension phases</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 107                                                                                                                           Incidence rate of FVIII inhibitors (≥0.6 BU): Extension phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 108                                                                                                        Incidence rate of FVIII inhibitors (≥0.6 BU): Combined main and extension phases</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 109                                                                                                                                            Incidence rate of FVIII inhibitors (≥0.6 BU)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 110                                  Haemostatic effect of turoctocog alfa on treatment of bleeds assessed on a predefined four point scale: Excellent, Good, Moderate and None: Main phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 111                             Haemostatic effect of turoctocog alfa on treatment of bleeds assessed on a predefined four point scale: Excellent, Good, Moderate and None: Extension phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 112          Haemostatic effect of turoctocog alfa on treatment of bleeds assessed on a predefined four point scale: excellent, good, moderate and none: Combined main and extension phases</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 113                                                                                                                                                    Annualised bleeding rate: Main phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 114                                                                                                                                               Annualised bleeding rate: Extension phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 115                                                                                                                            Annualised bleeding rate: Combined main and extension phases</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 116                                                                                                                           Incidence rate of FVIII inhibitors (≥0.6 BU): Extension phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 117                                                                                                        Incidence rate of FVIII inhibitors (≥0.6 BU): Combined main and extension phases</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 118                                                                                                                                            Incidence rate of FVIII inhibitors (≥0.6 BU)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 119                                  Haemostatic effect of turoctocog alfa on treatment of bleeds assessed on a predefined four point scale: Excellent, Good, Moderate and None: Main phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 120                             Haemostatic effect of turoctocog alfa on treatment of bleeds assessed on a predefined four point scale: Excellent, Good, Moderate and None: Extension phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 121          Haemostatic effect of turoctocog alfa on treatment of bleeds assessed on a predefined four point scale: excellent, good, moderate and none: Combined main and extension phases</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 122                                                                                                                                                    Annualised bleeding rate: Main phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 123                                                                                                                                               Annualised bleeding rate: Extension phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 124                                                                                                                            Annualised bleeding rate: Combined main and extension phases</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 125                                                                                                                           Incidence rate of FVIII inhibitors (≥0.6 BU): Extension phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 126                                                                                                        Incidence rate of FVIII inhibitors (≥0.6 BU): Combined main and extension phases</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 127                                                                                                                                            Incidence rate of FVIII inhibitors (≥0.6 BU)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 128                                  Haemostatic effect of turoctocog alfa on treatment of bleeds assessed on a predefined four point scale: Excellent, Good, Moderate and None: Main phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 129                             Haemostatic effect of turoctocog alfa on treatment of bleeds assessed on a predefined four point scale: Excellent, Good, Moderate and None: Extension phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 130          Haemostatic effect of turoctocog alfa on treatment of bleeds assessed on a predefined four point scale: excellent, good, moderate and none: Combined main and extension phases</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 131                                                                                                                                                    Annualised bleeding rate: Main phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 132                                                                                                                                               Annualised bleeding rate: Extension phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 133                                                                                                                            Annualised bleeding rate: Combined main and extension phases</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 134                                                                                                                           Incidence rate of FVIII inhibitors (≥0.6 BU): Extension phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 135                                                                                                        Incidence rate of FVIII inhibitors (≥0.6 BU): Combined main and extension phases</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 136                                                                                                                                            Incidence rate of FVIII inhibitors (≥0.6 BU)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 137                                  Haemostatic effect of turoctocog alfa on treatment of bleeds assessed on a predefined four point scale: Excellent, Good, Moderate and None: Main phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 138                             Haemostatic effect of turoctocog alfa on treatment of bleeds assessed on a predefined four point scale: Excellent, Good, Moderate and None: Extension phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 139          Haemostatic effect of turoctocog alfa on treatment of bleeds assessed on a predefined four point scale: excellent, good, moderate and none: Combined main and extension phases</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 140                                                                                                                                                    Annualised bleeding rate: Main phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 141                                                                                                                                               Annualised bleeding rate: Extension phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 142                                                                                                                            Annualised bleeding rate: Combined main and extension phases</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 143                                                                                                                           Incidence rate of FVIII inhibitors (≥0.6 BU): Extension phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 144                                                                                                        Incidence rate of FVIII inhibitors (≥0.6 BU): Combined main and extension phases</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 145                                                                                                                                            Incidence rate of FVIII inhibitors (≥0.6 BU)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 146                                  Haemostatic effect of turoctocog alfa on treatment of bleeds assessed on a predefined four point scale: Excellent, Good, Moderate and None: Main phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 147                             Haemostatic effect of turoctocog alfa on treatment of bleeds assessed on a predefined four point scale: Excellent, Good, Moderate and None: Extension phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 148          Haemostatic effect of turoctocog alfa on treatment of bleeds assessed on a predefined four point scale: excellent, good, moderate and none: Combined main and extension phases</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 149                                                                                                                                                    Annualised bleeding rate: Main phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 150                                                                                                                                               Annualised bleeding rate: Extension phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 151                                                                                                                            Annualised bleeding rate: Combined main and extension phases</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 152                                                                                                                           Incidence rate of FVIII inhibitors (≥0.6 BU): Extension phase</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 153                                                                                                        Incidence rate of FVIII inhibitors (≥0.6 BU): Combined main and extension phases</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 154                                                                                                                                                                Time to Overall Response</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 155                                                                                                                                                            Durability of First Response</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 156                                                                                                                                                                   Glucocortoid Tapering</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 157                                                                                                                                                                       Survival Pre-HSCT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 158                                                                                                                                                                        Overall Survival</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 159                                                                                                                                                                        Overall Response</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 160                                                                                                                                                                      Survival Post-HSCT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 161                                                                                                                                                         Cumulative Duration of Response</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 162                                                                                                                                                                Time to Overall Response</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 163                                                                                                                                                            Durability of First Response</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 164                                                                                                                                                                   Glucocortoid Tapering</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 165                                                                                                                                                                       Survival Pre-HSCT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 166                                                                                                                                                                        Overall Survival</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 167                                                                                                                                                                        Overall Response</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 168                                                                                                                                                                      Survival Post-HSCT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 169                                                                                                                                                         Cumulative Duration of Response</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 170                                                                                                                                                                Time to Overall Response</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 171                                                                                                                                                            Durability of First Response</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 172                                                                                                                                                                   Glucocortoid Tapering</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 173                                                                                                                                                                       Survival Pre-HSCT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 174                                                                                                                                                                        Overall Survival</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 175                                                                                                                                                                        Overall Response</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 176                                                                                                                                                                      Survival Post-HSCT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 177                                                                                                                                                         Cumulative Duration of Response</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 178                                                                                                                                                                Time to Overall Response</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 179                                                                                                                                                            Durability of First Response</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 180                                                                                                                                                                   Glucocortoid Tapering</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 181                                                                                                                                                                       Survival Pre-HSCT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 182                                                                                                                                                                        Overall Survival</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 183                                                                                                                                                                        Overall Response</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 184                                                                                                                                                                      Survival Post-HSCT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 185                                                                                                                                                         Cumulative Duration of Response</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 186                                                                                                                                                                Time to Overall Response</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 187                                                                                                                                                            Durability of First Response</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 188                                                                                                                                                                   Glucocortoid Tapering</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 189                                                                                                                                                                       Survival Pre-HSCT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 190                                                                                                                                                                        Overall Survival</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 191                                                                                                                                                                        Overall Response</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 192                                                                                                                                                                      Survival Post-HSCT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 193                                                                                                                                                         Cumulative Duration of Response</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 194                                                                                                                                                                Time to Overall Response</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 195                                                                                                                                                            Durability of First Response</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 196                                                                                                                                                                   Glucocortoid Tapering</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 197                                                                                                                                                                       Survival Pre-HSCT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 198                                                                                                                                                                        Overall Survival</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 199                                                                                                                                                                        Overall Response</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 200                                                                                                                                                                      Survival Post-HSCT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 201                                                                                                                                                         Cumulative Duration of Response</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 202                                                                                                                                                                Time to Overall Response</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 203                                                                                                                                                            Durability of First Response</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 204                                                                                                                                                                   Glucocortoid Tapering</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 205                                                                                                                                                                       Survival Pre-HSCT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 206                                                                                                                                                                        Overall Survival</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 207                                                                                                                                                                        Overall Response</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 208                                                                                                                                                                      Survival Post-HSCT</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 209                                                                                                                                                         Cumulative Duration of Response</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 210                                                                         Percentage of Subjects With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 211                                                                         Annualized Number of Bleeding Episodes (Spontaneous and Traumatic) per Subject (Annualized Bleeding Rate [ABR])</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 212                                                                                                                                Annualized Number of Spontaneous Joint Bleeding Episodes</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 213                                                                  Number of rFIXFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 214                                                                                                                                                     Total Number of Exposure Days (EDs)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 215                                                                                   Total Annualized rFIXFc Consumption per Subject for the Prevention and Treatment of Bleeding Episodes</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 216                                                                                                                   Number of Injections of rFIXFc Required to Resolve a Bleeding Episode</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 217                                                                                                             Average dose per Injection of rFIXFc Required to Resolve a Bleeding Episode</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 218                                                                                                                                Change From Baseline in rFIXFc Incremental Recovery (IR)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 219                                                                         Percentage of Subjects With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 220                                                                         Annualized Number of Bleeding Episodes (Spontaneous and Traumatic) per Subject (Annualized Bleeding Rate [ABR])</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 221                                                                                                                                Annualized Number of Spontaneous Joint Bleeding Episodes</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 222                                                                  Number of rFIXFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 223                                                                                                                                                     Total Number of Exposure Days (EDs)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 224                                                                                   Total Annualized rFIXFc Consumption per Subject for the Prevention and Treatment of Bleeding Episodes</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 225                                                                                                                   Number of Injections of rFIXFc Required to Resolve a Bleeding Episode</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 226                                                                                                             Average dose per Injection of rFIXFc Required to Resolve a Bleeding Episode</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 227                                                                                                                                Change From Baseline in rFIXFc Incremental Recovery (IR)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 228                                                                         Percentage of Subjects With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 229                                                                         Annualized Number of Bleeding Episodes (Spontaneous and Traumatic) per Subject (Annualized Bleeding Rate [ABR])</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 230                                                                                                                                Annualized Number of Spontaneous Joint Bleeding Episodes</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 231                                                                  Number of rFIXFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 232                                                                                                                                                     Total Number of Exposure Days (EDs)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 233                                                                                   Total Annualized rFIXFc Consumption per Subject for the Prevention and Treatment of Bleeding Episodes</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 234                                                                                                                   Number of Injections of rFIXFc Required to Resolve a Bleeding Episode</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 235                                                                                                             Average dose per Injection of rFIXFc Required to Resolve a Bleeding Episode</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 236                                                                                                                                Change From Baseline in rFIXFc Incremental Recovery (IR)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 237                                                                         Percentage of Subjects With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 238                                                                         Annualized Number of Bleeding Episodes (Spontaneous and Traumatic) per Subject (Annualized Bleeding Rate [ABR])</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 239                                                                                                                                Annualized Number of Spontaneous Joint Bleeding Episodes</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 240                                                                  Number of rFIXFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 241                                                                                                                                                     Total Number of Exposure Days (EDs)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 242                                                                                   Total Annualized rFIXFc Consumption per Subject for the Prevention and Treatment of Bleeding Episodes</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 243                                                                                                                   Number of Injections of rFIXFc Required to Resolve a Bleeding Episode</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 244                                                                                                             Average dose per Injection of rFIXFc Required to Resolve a Bleeding Episode</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 245                                                                                                                                Change From Baseline in rFIXFc Incremental Recovery (IR)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 246                                                                         Percentage of Subjects With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 247                                                                         Annualized Number of Bleeding Episodes (Spontaneous and Traumatic) per Subject (Annualized Bleeding Rate [ABR])</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 248                                                                                                                                Annualized Number of Spontaneous Joint Bleeding Episodes</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 249                                                                  Number of rFIXFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 250                                                                                                                                                     Total Number of Exposure Days (EDs)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>     item</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 1      1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 2      2</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 3      3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 4      4</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 5      5</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 6      6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 7      1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 8      2</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 9      3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 10     4</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 11     5</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 12     6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 13     1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 14     2</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 15     3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 16     4</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 17     5</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 18     6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 19     1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 20     2</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 21     3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 22     4</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 23     5</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 24     6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 25     1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 26     2</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 27     3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 28     4</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 29     5</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 30     6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 31     1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 32     2</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 33     3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 34     4</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 35     5</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 36     6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 37     1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 38     2</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 39     3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 40     4</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 41     5</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 42     6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 43     1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 44     2</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 45     3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 46     4</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 47     5</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 48     6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 49     1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 50     2</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 51     3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 52     4</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 53     5</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 54     6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 55     1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 56     2</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 57     3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 58     4</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 59     5</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 60     6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 61     1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 62     2</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 63     3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 64     4</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 65     5</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 66     6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 67     1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 68     2</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 69     3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 70     4</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 71     5</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 72     6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 73     1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 74     2</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 75     3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 76     4</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 77     5</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 78     6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 79     7</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 80     8</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 81     9</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 82     1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 83     2</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 84     3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 85     4</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 86     5</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 87     6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 88     7</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 89     8</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 90     9</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 91     1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 92     2</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 93     3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 94     4</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 95     5</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 96     6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 97     7</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 98     8</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 99     9</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 100    1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 101    2</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 102    3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 103    4</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 104    5</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 105    6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 106    7</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 107    8</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 108    9</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 109    1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 110    2</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 111    3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 112    4</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 113    5</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 114    6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 115    7</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 116    8</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 117    9</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 118    1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 119    2</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 120    3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 121    4</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 122    5</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 123    6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 124    7</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 125    8</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 126    9</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 127    1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 128    2</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 129    3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 130    4</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 131    5</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 132    6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 133    7</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 134    8</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 135    9</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 136    1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 137    2</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 138    3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 139    4</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 140    5</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 141    6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 142    7</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 143    8</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 144    9</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 145    1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 146    2</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 147    3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 148    4</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 149    5</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 150    6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 151    7</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 152    8</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 153    9</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 154    1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 155    2</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 156    3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 157    4</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 158    5</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 159    6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 160    7</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 161    8</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 162    1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 163    2</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 164    3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 165    4</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 166    5</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 167    6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 168    7</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 169    8</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 170    1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 171    2</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 172    3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 173    4</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 174    5</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 175    6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 176    7</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 177    8</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 178    1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 179    2</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 180    3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 181    4</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 182    5</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 183    6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 184    7</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 185    8</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 186    1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 187    2</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 188    3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 189    4</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 190    5</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 191    6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 192    7</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 193    8</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 194    1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 195    2</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 196    3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 197    4</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 198    5</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 199    6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 200    7</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 201    8</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 202    1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 203    2</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 204    3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 205    4</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 206    5</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 207    6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 208    7</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 209    8</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 210    1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 211    2</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 212    3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 213    4</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 214    5</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 215    6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 216    7</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 217    8</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 218    9</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 219    1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 220    2</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 221    3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 222    4</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 223    5</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 224    6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 225    7</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 226    8</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 227    9</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 228    1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 229    2</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 230    3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 231    4</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 232    5</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 233    6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 234    7</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 235    8</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 236    9</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 237    1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 238    2</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 239    3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 240    4</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 241    5</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 242    6</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 243    7</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 244    8</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 245    9</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 246    1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 247    2</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 248    3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 249    4</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 250    5</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  [ reached 'max' / getOption("max.print") -- omitted 481 rows ]</span>
<span class="r-in"><span></span></span>
</code></pre></div>
    </div>
  </main><aside class="col-md-3"><nav id="toc"><h2>On this page</h2>
    </nav></aside></div>


    <footer><div class="pkgdown-footer-left">
  <p></p><p>Developed by Ralf Herold.</p>
</div>

<div class="pkgdown-footer-right">
  <p></p><p>Site built with <a href="https://pkgdown.r-lib.org/" class="external-link">pkgdown</a> 2.0.6.</p>
</div>

    </footer></div>

  

  

  </body></html>

